Overview

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

Status:
TERMINATED

Trial end date:
2021-09-23

Target enrollment:

Participant gender:

Summary

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess the clinical activity of novel regimen (Feladilimab plus Ipilimumab) in participants with NSCLC.

Phase:

PHASE2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Ipilimumab